Influence of Androgen Suppression Therapy for Prostate Cancer on the Frequency and Timing of Fatal Myocardial Infarctions

D'Amico, Anthony V., Denham, James W., Crook, Juanita, Chen, Ming-Hui, Goldhaber, Samuel Z., Lamb, David S., Joseph, David, Tai, Keen-Hun +4 more·2007·Journal of Clinical Oncology
DOI 10.1200/jco.2006.09.3369

Cited by (502)

Items 401–500 of 502

  1. Enquête observationnelle, transversale de l’Association française d’urologie (AFU) sur la pratique du traitement hormonal intermittent dans le cancer de la prostate en France
    Laurent Salomon, Guillaume Ploussard, Patrick J. Coloby, G. Kouri, Thierry Lebrét, A. Méjean, Denis Prunet, Michel Soulie · 2013 · The French Journal of Urology
  2. Long-term PSA-free survival and castration-free survival with delayed antiandrogen therapy in patients with one versus two or more positive nodes at prostatectomy
    Michele Lodde, Louis Lacombe, Angelo Naselli, Paolo Puppo, Michael Mian, Yves Fradet · 2012 · World Journal of Urology
  3. Riscos Cardiovasculares do Bloqueio Androgênico
    Serrano Jr, Carlos V. · 2010 · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
  4. HIGH-RISK PROSTATE CANCER: THE ONCOLOGICAL EFFICIENCY OF RADICAL PROSTATECTOMY
    E. I. Veliyev, Sokolov Ea, Oleg B. Loran, С. Б. Петров · 2014 · DOAJ (DOAJ: Directory of Open Access Journals)
  5. Kardiovaskuläre Risiken der Androgendeprivationstherapie beim Prostatakarzinom
    K. Miller · 2016 · Der Urologe
  6. Anti-Androgen Therapy Suspension following Prolonged Clinical and Biochemical Response: Outcomes in a Series of Elderly Patients with Advanced Prostate Cancer
    Bruno Castagneto, Ilaria Stevani, Valentino Ferraris, Laura Giorcelli, Massimo Perachino · 2010 · Tumori Journal
  7. Prostate Cancer and the Metabolic Syndrome
    Stephen E M Langley, Jenny Penelope Nobes · 2012 · Springer eBooks
  8. Systemic complications in the hormonal treatment of prostate and breast cancer
    Beata Jagielska, Grażyna Poniatowska, Konrad Tałasiewicz, Tomasz Demkow, Paweł Wiechno · 2017 · Nowotwory Journal of Oncology
  9. Prostate cancer update: 2007
    Amy Lin, Eric Jay Small · 2008 · Current Opinion in Internal Medicine
  10. Antihormonelle Therapie des Prostatakarzinoms − Behandlungsindikation und kardiovaskuläres Risikoprofil − Vorteil für GnRH-Antagonisten?
    Thomas Höfner · 2018 · Aktuelle Urologie
  11. Survival and mortality of elderly men with localized prostate cancer managed with primary androgen deprivation therapy or by primary observation
    Heikki A. Seikkula, Peter J. Boström, Karri Seppä, Janne M. Pitkäniemi, Nea K. Malila, Antti J. Kaipia · 2020 · BMC Urology
  12. Genitourinary Cancer
    Bertrand F. TOMBAL · 2012 · Springer eBooks
  13. Combination of Androgen Deprivation Therapy and Radiation Therapy for Locally Advanced and Localized Prostate Cancer
    M. Bolla, Camille Verry · 2012 · Springer eBooks
  14. Cardiac Mechanics in Altered Hormonal States as a Surrogate for Understanding the Effects of Transgender Hormone Therapy
    Rohitha A. Moudgal, David C. Peritz, John H. Turco, Cynthia C. Taub · 2022 · Cardiology in Review
  15. Evolving Prostate Cancer Radiotherapy: Exploring Gonadal Doses in 3DCRT and IMRT with Testicular Shielding
    Tavseef Ahmad Tali, Mohsin Rehman Khan, Aijaz Ahmad Khan, Adham Riaz, Saqib Javed · 2024 · Asian Pacific Journal of Cancer Care
  16. Hormonal Therapy and Radiation Therapy: Randomized and Prospective Trials
    M. Bolla, Camille Verry, Violaine Brun Baronnat, Alexandre Tessier · 2014 · Medical radiology
  17. Cardiovascular mortality in patients with prostate cancer receiving androgen deprivation therapy
    Juan Ignacio Monzó Gardiner, Felipe Herranz-Amo · 2015 · Actas Urológicas Españolas (English Edition)
  18. Androgen Deprivation Therapy for Prostate Cancer
    2017 · BENTHAM SCIENCE PUBLISHERS eBooks
  19. The Effects of Age, Ethnicity, Sexual Dysfunction, Urinary Incontinence, Masculinity, and Relationship with the Partner on the Quality of Life of Men with Prostate Cancer
    Suha Ballout · 2013
  20. Exercise as medicine : reversing treatment toxicities in prostate cancer patients
    Bradley A. Wall · 2013 · Australasian Journal of Paramedicine
  21. The Motion: Hormonal Blockade Should be Limited Due to Significant Adverse Effects
    LAURENT BOCCON-GIBOD, Bertrand F. TOMBAL · 2008 · European Urology
  22. Does androgen deprivation therapy in men with prostate cancer increase cardiovascular morbidity?
    Steven M. Corsello, Philip W. Kantoff · 2007 · Nature Clinical Practice Urology
  23. Unanswered Questions Regarding the Effect of Androgen Deprivation Therapy for Prostate Cancer on Cardiovascular Disease Risk in Black Men
    Karen Marie Winkfield, Michelle Asha Albert · 2010 · Current Cardiovascular Risk Reports
  24. Cardiovascular Disease With Androgen Deprivation: The (forgotten) Role of Testosterone
    Jeanny B. Aragon‐Ching · 2009 · Journal of Clinical Oncology
  25. The Hormonal Management of Metastatic Prostate Cancer
    Tanya Barauskas Dorff, Jacek Pinski · 2014 · Springer eBooks
  26. Prostate Cancer
    Siavash Jabbari, Eric K. Hansen, Mack Roach · 2010 · Springer eBooks
  27. Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors
    Matthew R. Smith · 2008 · Current Prostate Reports
  28. Les effets secondaires de l’hormonothérapie et leur gestion
    Christophe Hennequin, Pierre Mongiat-Artus, L. Quéro, Damien Pouessel, Stéphane Culine · 2012 · ONCOLOGIE
  29. Hormones in cancer
    Jacinta Abraham, John Nicholas Staffurth · 2015 · Cambridge University Press eBooks
  30. The Value of Progress against Cancer in the Elderly
    Jay Bhattacharya, Alan M. Garber, Matthew Miller, Daniella J. Perlroth · 2012 · University of Chicago Press eBooks
  31. Re: Adjuvant Weekly Docetaxel for Patients with High Risk Prostate Cancer after Radical Prostatectomy: A Multi-institutional Pilot Study
    Derek Raghavan · 2007 · European Urology
  32. Cáncer de próstata, terapia antiandrogénica y riesgo cardiovascular
    Santiago Reinoso Hermida, Gabriel J. Díaz Grávalos, Aida Robles Castiñeiras, Clara Villar Latorre, Ana López González, Antonio Ojea Calvo · 2011 · Atención Primaria
  33. Reply to J.B. Aragon-Ching
    Shabbir M.H. Alibhai · 2009 · Journal of Clinical Oncology
  34. Re: Androgen Deprivation Therapy for Localized Prostate Cancer and the Risk of Cardiovascular Mortality
    Pierre Mongiat-Artus · 2008 · European Urology
  35. The Use of Androgen Deprivation in Conjunction with Radiation in Localized Prostate Cancer
    Omar Mahmoud, May Abdel–Wahab · 2010 · The Open Prostate Cancer Journal
  36. The clinical significance of biochemical failure in the first 2 years in patients treated with neo-adjuvant androgen deprivation and radiotherapy for prostate cancer
    Fergal C. Kelleher, Dunne MT, Collins IM, Finn MA, C. O'Shea, Armstrong Jg · 2013 · Oncology Discovery
  37. Does Primary Androgen-Deprivation Therapy Improve Survival for Localized Prostate Cancer?
    Stacy Loeb, Edward Matthew Schaeffer · 2008 · Aging Health
  38. Re: Toremifene Improves Lipid Profiles in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer: Interim Analysis of a Multicenter Phase III Study
    Bertrand F. TOMBAL · 2008 · European Urology
  39. Hormonal therapy and radiation for prostate cancer: is it safe?
    Akash Nanda, Anthony Victor D'Amico · 2010 · Expert Review of Anticancer Therapy
  40. Le traitement hormonal du cancer de la prostate chez le patient âgé
    Pierre Mongiat-Artus, Michaël Peyromaure, Pierre M. Richaud, Philippe Beuzeboc, C. Bastide, François Cornud, N. Gaschignard, Vincent Molinié, François Rozet, Frédéric Staerman et al. · 2009 · The French Journal of Urology
  41. RETRACTED ARTICLE: Importance of hypogonadism and testosterone replacement therapy in current urologic practice: a review
    Maurizio Buscarini, Antonio Cardi · 2010 · International Urology and Nephrology · Retracted
  42. Re: Mieke Van Hemelrijck, Hans Garmo, Lars Holmberg, et al. Multiple Events of Fractures and Cardiovascular and Thromboembolic Disease Following Prostate Cancer Diagnosis: Results From the Population-Based PCBaSe Sweden. Eur Urol 2012;61:690–700
    Tommaso Cai, Carolina D’Elia, Beatrice Detti · 2011 · European Urology
  43. What effect does androgen suppression therapy have on frequency and timing of fatal myocardial infarctions?
    Jeffrey M. Holzbeierlein · 2007 · Nature Clinical Practice Oncology
  44. Updated Analysis of RTOG 94-13: In Regard to Lawton et al. (Int J Radiat Oncol Biol Phys 2007;69:646–655)
    Scott Williams, Kirsty L. Wiltshire · 2008 · International Journal of Radiation Oncology*Biology*Physics
  45. Testosterone and Its Association with Metabolic and Cardiovascular Disease
    Giovanni Corona, Giulia Rastrelli, Mario Maggi · 2012 · Humana Press eBooks
  46. Metabolic and cardiovascular risks of androgen-deprivation therapy for prostate cancer
    Vinod E. Nambudiri, Nancy Lynn Keating · 2010 · Expert Review of Endocrinology & Metabolism
  47. Disorders of male fertility
    Linda D. Applegarth, Robert Davis Oates, Peter N. Schlegel · 2013 · Cambridge University Press eBooks
  48. Pitfalls of Androgen Deprivation Therapy
    Alicia Katherine Morgans, Matthew R. Smith · 2012 · Humana Press eBooks
  49. Prognostic Factors of Localized Prostate Cancer in Elderly Patients
    Barry B. McGuire, John M. Fitzpatrick · 2012 · Springer eBooks
  50. THE PHYSIOLOGICAL AND PSYCHOSOCIAL EFFECTS OF A 16-WEEK COMBINED AEROBIC AND RESISTANCE EXERCISE PROGRAM IN MEN RECEIVING ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCER
    Robyn M. Murphy · 2011 · Library and Archives Canada (Government of Canada)
  51. Testosterone is Protective against Cardiac Disease: Pro
    Mohit Khera · 2016 · The Journal of Urology
  52. Syndrome métabolique et insulinorésistance chez les patients atteints de cancer de la prostate traités par suppression androgénique hormonale Metabolic syndrome and insulin resistance in patients with prostate cancer treated with androgen deprivation hormone
    Jean E. Terrier, Nicolas Mottet · 2013
  53. Prämature Atherosklerose
    Dietrich Strödter · 2007 · Gefässchirurgie
  54. Acute Versus Chronic Exposure to Androgen Suppression for Prostate Cancer: Impact on the Exercise Response
    Roy Jesse Shephard · 2012 · Yearbook of Sports Medicine
  55. Contemporary Role of Endocrine Treatment in Patients with Localized or Locally Advanced Prostate Cancer: A Review
    Vallejo Herrador J, L. Martínez-Piñeiro · 2011 · Current Cancer Therapy Reviews
  56. Cardiovascular risk associated with androgen deprivation therapy.
    Monika Jacquelina Leja, Edward T.H. Yeh · 2010 · PubMed
  57. Androgen-Deprivation Therapy and MIs in Men with Prostate Cancer
    Robert Dreicer, FACP. FACP. · 2007 · Journal watch
  58. Gleason score and the risk of cause-specific and all-cause mortality following radiation with or without 6 months of androgen deprivation therapy for men with unfavorable-risk prostate cancer
    Laura Elizabeth Warren, Ming‐Hui Chen, James William Denham, Allison Steigler, Andrew A. Renshaw, Marian J. Loffredo, Philip W. Kantoff, Anthony Victor D'Amico · 2016 · Journal of Radiation Oncology
  59. Efecto precoz de la deprivación androgénica sobre la sarcopenia. Valoración de la masa muscular mediante TC y DEXA
    Bestard Vallejo, Edgard San Juan · 2012 · TDX (Tesis Doctorals en Xarxa)
  60. Dilated Cardiomyopathy after Sequential Therapy with Abiraterone and Enzalutamide
    Freeman B, J Wang · 2016 · Oncology & Cancer Case Reports
  61. Gleason score and the risk of cause-specific and overall mortality following radiation with or without 6 months of androgen deprivation therapy for men with unfavorable-risk prostate cancer.
    Laura Elizabeth Warren, Ming‐Hui Chen, James William Denham, Allison Steigler, Andrew A. Renshaw, Marian J. Loffredo, Philip W. Kantoff, Anthony Victor D'Amico · 2016 · Journal of Clinical Oncology
  62. A low cost, efficient method for chip fabrication in cell analysis
    Ali Rahmani, Aliasghar Mohammadi, Hamid Reza Kalhor · 2016 · National and International Iranian Conference on Biomedical Engineering (ICBME)
  63. Hypofractionated Radiotherapy in Genitourinary Cancer: Better with Less
    Ruud C. Wortel, Luca Incrocci · 2017 · Medical radiology
  64. Collaborative Review - Prostate Cancer Androgen Deprivation Therapy for the Treatment of Prostate Cancer: Consider Both Benefits and Risks
    Hendrik Isbarn A, LAURENT BOCCON-GIBOD, Peter R. Carroll, Francesco Montorsi, Claude Schulman, Matthew R. Smith, Cora Nanette Sternberg, Urs E. Studer · 2009
  65. Prevalencia de Eventos Cardiocerebrovasculares en Pacientes con Cáncer de Próstata en Manejo con Bloqueo Androgénico con Análogo de GNRH
    José Poveda, Cesar González, William Quiroga Matamoros, Margarita Zapata, Sebastián Baena Acosta · 2018 · Revista Urología Colombiana / Colombian Urology Journal
  66. Antihormonelle Therapie des Prostatakarzinoms − Behandlungsindikation und kardiovaskuläres Risikoprofil − Vorteil für GnRH-Antagonisten?
    Thomas Höfner · 2018 · Aktuelle Urologie
  67. Prostate Cancer
    Vikas Kundra, Surena F. Matin, Deborah Ann Kuban · 2012 · Elsevier eBooks
  68. Editorial Comment
    Takashi Kobayashi · 2008 · The Journal of Urology
  69. Actual questions of medicine therapy of hormonoresistant and metastatic prostate cancer
    А. Д. Каприн, R A Gafanov, M Kh Shaipov, А. В. Шестаков, A V Meskich · 2010 · Medical academic journal
  70. Investigations in the Economics of Aging
    Jay Bhattacharya, Alan M. Garber, Matthew Miller, Daniella J. Perlroth · RePEc: Research Papers in Economics
  71. Diferelin® as an effective chemical castration agent for patients with prostate cancer
    K. М. Nyushko, V. M. Perepukhov, B. Yа. Alekseev · 2020 · Cancer Urology
  72. The anti-inflammatory effects of testosterone on atherosclerosis
    Lauren Bateman · 2020 · Sheffield Hallam University
  73. Einflussfaktoren bei der Wahl der Androgendeprivationstherapie für Patienten mit hormonsensitiven Prostatakarzinom
    J. Lehmann, C. W. Kluike, Ahmad Haider, Karim Sultan Haider, S. Baumann, Markus Flesch, Michael Gedamke, Danny Kägebein · 2021 · Der Urologe
  74. Editorial Comment: Testosterone replacement therapy (TRT) and prostate cancer: An updated systematic review with a focus on previous or active localized prostate cancer
    Valter Javaroni · 2022 · International braz j urol
  75. Radiation Therapy in the Management of Locally Advanced Prostate Cancer
    Joseph Douglas Mancias, Anthony Laurence Zietman · 2012 · Humana Press eBooks
  76. Prostate cancer : epidemiological studies of risk factors
    Camilla Thellenberg Karlsson · 2008
  77. Comparison of Definitive Radiotherapy in the Young-Elderly and Elderly with Clinical Localized Prostate Cancer
    Berrin İnanç, Özlem Mermut, Begüm Ökten, Ozlem Besikci, Ebru Tuncay, Caner Aktaş · 2021 · Istanbul Medical Journal
  78. Current World Literature
    2008 · Current Opinion in Endocrinology Diabetes and Obesity
  79. Cancer survivorship and comorbidity disease risk after cancer treatment
    Suparna Chandra Clasen, Lavanya Kondapalli, Joseph R. Carver · 2022 · Elsevier eBooks
  80. Neoplasms of the Prostate
    Christopher J. Logothetis, Jeri Kim, John Warren Davis, Brian Francis Chapin, Deborah Ann Kuban, Eleni Efstathiou, Ana M. Aparicio · 2017 · Holland‐Frei Cancer Medicine
  81. Prostate Cancer
    Jeff M. Michalski, Thomas Michael Pisansky, C.A. Lawton, Louis Potters, Deborah Ann Kuban · 2012 · Elsevier eBooks
  82. Editorial Comment
    Mitchell C. Benson · 2008 · The Journal of Urology
  83. In Reply
    Anthony Victor D'Amico, Ming‐Hui Chen · 2007 · Journal of Clinical Oncology
  84. Urological Oncology: Prostate Cancer
    Patrick C. Walsh · 2008 · The Journal of Urology
  85. Miscellaneous hormones
    R.C.L. Page · 2010 · Side effects of drugs annual
  86. Gonadotropins
    2015 · Elsevier eBooks
  87. Combination of Androgen Deprivation Therapy and Radiation Therapy for Locally Advanced and Localized Prostate Cancer
    M. Bolla, Camille Verry, Carole Iriart · 2017 · Springer eBooks
  88. Androgen Deficiency
    Mathew Raynor, Michael R. Pinsky, Arthi Chawla, Wayne J.G. Hellstrom · 2011 · Humana Press eBooks
  89. Androgen suppression therapy increases the risk of myocardial infarction in older men
    2007 · Nature Clinical Practice Urology
  90. Evaluation of primary androgen deprivation therapy in prostate cancer patients using the J-CAPRA risk score
    Hideyuki Akaza, Shiro Hinotsu, Michiyuki Usami, Osamu Ogawa, Tadaichi Kitamura, Kazuhiro Suzuki, Taiji Tsukamoto, Seiji Naito, Mikio Namiki, Yoshihiko Hirao et al. · 2013 · Prostate International
  91. Role of HMG-CoA reductase inhibitors with curative radiotherapy in men with prostate cancer
    Stanley L. Liauw · 2011 · Research and Reports in Urology
  92. Neoplasms of the Prostate
    Ana M. Aparicio, Patrick Glen Pilie, Devaki Shilpa Surasi, Seungtaek Choi, Brian Francis Chapin, Christopher J. Logothetis, Paul Gettys Corn · 2022 · Holland‐Frei Cancer Medicine
  93. Prostate Cancer: A State of The Heart
    Tabasum Mughal · 2014 · EMJ Urology
  94. The Effect of Age on Clinicopathological Features and Treatment Outcomes of Patients Receiving Definitive Radiotherapy for Localized Prostate Cancer
    Cem Önal, Ozan Cem Güler, Ayşenur Elmalı, Melek Yavuz · 2024 · SSRN Electronic Journal
  95. Time to Benefit of Androgen Deprivation Therapy in Patients With Localized Prostate Cancer Undergoing Radiotherapy
    Jing Wang, Xiangwei Hou, Leixuan Peng, Yongze Dang, Xiangyu Xu, Chenyu Wei, Ruishan Guo, Wenfei Song, Chenchen He, Jiaqi Jiang et al. · 2025 · JCO Precision Oncology
  96. Additional file 1 of Survival and mortality of elderly men with localized prostate cancer managed with primary androgen deprivation therapy or by primary observation
    Heikki A. Seikkula, Boström, Peter J., Karri Seppä, Janne M. Pitkäniemi, Malila, Nea, Antti J. Kaipia · 2020 · Figshare
  97. Altération de la qualité de vie sexuelle des patients atteints d'un cancer de la prostate : de la reconnaissance aux actions pour améliorer leur sexualité
    J. Terrier · 2019
  98. Radiotherapy Plus Hormonal Therapy
    Jordan A. Holmes, R. C. Chen · 2012 · Springer eBooks
  99. Development and External Validation of a Machine Learning–Based Risk Classification Score for Prostate Cancer–Specific Cardiovascular Risk
    Nickolas Stabellini, Tarek Nahle, Viraj Shah, Sai Suraj Kollapaneni, Omar Mohamed Makram, Jennifer Cullen, Neal L Weintraub, Harikrishnan Hyma Kunhiraman, Umang Swami, Morteza Mahmoudi et al. · 2026 · JCO Oncology Practice
  100. The relationship between prostate cancer and metabolic syndrome: A bibliometric analysis (2021–2023)
    Fang Wang, Juan Wu, Wanjiao Wang, Min Hu, Qinghong Xi · 2026 · Medicine